Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.71 |
| ▸ | RAF1 | P04049 | 5/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.47 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.47 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.47 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808543 | 0.91 | BRAF (0.72) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL3809266 | 0.90 | BRAF (0.63) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL3814156 | 0.84 | BRAF (0.68) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL3811056 | 0.84 | BRAF (0.70) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL3808571 | 0.83 | BRAF (0.84) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL3814445 | 0.83 | BRAF (0.72) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL13920818 | 0.83 | BRAF (0.65) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL2746166 | 0.83 | BRAF (1.00) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL3813148 | 0.83 | BRAF (1.00) | BRAFRAF1MAPK8PRKD3MAP4K4 | |
| SCHEMBL2745648 | 0.83 | BRAF (1.00) | BRAFRAF1MAPK8PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885MAPK8 301/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885MAPK8 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.